This research will assess the effects of Itacitinib as a second line treatment for patients
with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib
is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells
to metastasise to other parts of the body.